{"title":"骆驼来源的血红蛋白氧载体作为血液替代品的潜力","authors":"Mohamed Mostafa Shokry","doi":"10.4172/2155-952X.C1.061","DOIUrl":null,"url":null,"abstract":"Camel-derived haemoglobin O2 carriers (CHBOC) are being developed as a blood substitutes for allogeneic RBCs or to improve tissue oxygenation. The tolerability of the developed product was evaluated in 10 moderately exsanguinated (40%) experimental mongrel dogs that were randomized to receive either 40 g/l CHBOC dissolved in lactated Ringer’s solution at a rate of 5 ml/kg (Test group-14 trials) or 6 g/l HES 200 solution - 6% hydroxyethyl starch (Fresenius Kabi-Germany) dissolved in saline at a rate of - 5ml/kg- (Control group-6 trials). Overall, the clinical, haematological and biochemical responses were normal. The CHBOC was well tolerated and a promising product. However additional studies are needed to confirm the safety of the new CHBOC product in the realm of acellular blood transfusion.","PeriodicalId":15156,"journal":{"name":"Journal of biotechnology & biomaterials","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2016-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Potential of camel-derived hemoglobin oxygen carriers as a blood substitute\",\"authors\":\"Mohamed Mostafa Shokry\",\"doi\":\"10.4172/2155-952X.C1.061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Camel-derived haemoglobin O2 carriers (CHBOC) are being developed as a blood substitutes for allogeneic RBCs or to improve tissue oxygenation. The tolerability of the developed product was evaluated in 10 moderately exsanguinated (40%) experimental mongrel dogs that were randomized to receive either 40 g/l CHBOC dissolved in lactated Ringer’s solution at a rate of 5 ml/kg (Test group-14 trials) or 6 g/l HES 200 solution - 6% hydroxyethyl starch (Fresenius Kabi-Germany) dissolved in saline at a rate of - 5ml/kg- (Control group-6 trials). Overall, the clinical, haematological and biochemical responses were normal. The CHBOC was well tolerated and a promising product. However additional studies are needed to confirm the safety of the new CHBOC product in the realm of acellular blood transfusion.\",\"PeriodicalId\":15156,\"journal\":{\"name\":\"Journal of biotechnology & biomaterials\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-10-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of biotechnology & biomaterials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2155-952X.C1.061\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biotechnology & biomaterials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2155-952X.C1.061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Potential of camel-derived hemoglobin oxygen carriers as a blood substitute
Camel-derived haemoglobin O2 carriers (CHBOC) are being developed as a blood substitutes for allogeneic RBCs or to improve tissue oxygenation. The tolerability of the developed product was evaluated in 10 moderately exsanguinated (40%) experimental mongrel dogs that were randomized to receive either 40 g/l CHBOC dissolved in lactated Ringer’s solution at a rate of 5 ml/kg (Test group-14 trials) or 6 g/l HES 200 solution - 6% hydroxyethyl starch (Fresenius Kabi-Germany) dissolved in saline at a rate of - 5ml/kg- (Control group-6 trials). Overall, the clinical, haematological and biochemical responses were normal. The CHBOC was well tolerated and a promising product. However additional studies are needed to confirm the safety of the new CHBOC product in the realm of acellular blood transfusion.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
